(Nasdaq:IMMX) ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. FDA Approved Drug Trabectedin
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study